Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIRACTA THERAPEUTICS, INC.

(VIRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about VIRACTA THERAPEUTICS, INC.
01/04Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
PR
2021VIRACTA THERAPEUTICS, INC.(NASDAQGS : VIRX) added to NASDAQ Biotechnology Index
CI
2021Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index
PR
2021Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presenta..
CI
2021Viracta Says Epstein-Barr Therapy Had 40% Overall Response Rate in Trial; Shares Fall
MT
2021Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Sign..
CI
2021INSIDER SELL : Viracta Therapeutics
MT
2021Viracta Therapeutics Secures FDA Orphan Drug Designation for Lymphoma Combo Therapy
MT
2021Viracta Therapeutics Gets FDA Orphan Drug Designation for Nana-val
DJ
2021Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral ..
PR
2021Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporat..
AQ
2021Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
2021Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporat..
PU
2021SUNESIS : Q3 Earnings Snapshot
AQ
2021Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and O..
AQ
2021Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 Ameri..
AQ
2021Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and O..
PU
2021Viracta Therapeutics, Inc. Secures $50 Million Credit Facility from Silicon Valley Bank..
CI
2021VIRACTA THERAPEUTICS : Multinational trial expands Viracta's clinical-stage pipeline beyon..
PU
2021Viracta Therapeutics Starts Trial of Nanatinostat in Epstein-Barr Virus-Positive Solid ..
MT
2021Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) S..
CI
2021VIRACTA THERAPEUTICS, INC.(NASDAQGS : VIRX) added to S&P Global BMI Index
CI
2021VIRACTA : Therapeutics to Present at Upcoming Investor Conferences in September
PR
2021Viracta Up 5% After It Reacquires Rights to Combination Therapy in China
DJ
2021VIRACTA THERAPEUTICS : Reacquires Exclusive Rights to Combination Therapy Candidate for Ly..
MT
2021VIRACTA THERAPEUTICS : Reacquires Exclusive Development and Commercialization Rights for i..
PU
2021VIRACTA : Therapeutics Reacquires Exclusive Development and Commercialization Rights for i..
PR
2021VIRACTA THERAPEUTICS : Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. B..
AQ
2021VIRACTA THERAPEUTICS : Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. B..
PU
2021Viracta Therapeutics, Inc. Announces Board Appointments
CI
2021VIRACTA THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides Clinical..
PU
2021SUNESIS : Q2 Earnings Snapshot
AQ
2021VIRACTA : Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical..
PR
2021Viracta Therapeutics, Inc Announces Consolidated Unaudited Earnings Results for the Sec..
CI
2021VIRACTA THERAPEUTICS : Says FDA Greenlights Phase 1b/2 Trial in EBV+ Solid Tumors
MT
2021VIRACTA THERAPEUTICS : Announces FDA Clearance of IND Application for Phase 1b/2 Trial in ..
PU
2021VIRACTA THERAPEUTICS : Announces FDA Clearance of IND Application for Phase 1b/2 Trial in ..
PR
2021VIRACTA THERAPEUTICS : Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scien..
AQ
2021VIRACTA THERAPEUTICS : Announces its Addition to the Russell 2000 Index and other FTSE Rus..
AQ
2021VIRACTA THERAPEUTICS : Announces its Addition to the Russell 2000« Index and other FTSE Ru..
PR
2021SUNESIS : Q1 Earnings Snapshot
AQ
2021VIRACTA THERAPEUTICS : Jefferies Virtual Healthcare Conference Presentation
PU
2021VIRACTA THERAPEUTICS : Initiates Phase 2 Trial to Evaluate Nanatinostat-Valganciclovir Com..
MT
2021Viracta Therapeutics, Inc. Announces the Initiation of Naval-1, A Global Pivotal Trial ..
CI
2021VIRACTA THERAPEUTICS : Files $200 Million Mixed Shelf
MT
2021VIRACTA THERAPEUTICS : At-The-Market Agreement (Form 8-K)
PU
2021Viracta Therapeutics, Inc.'s Subsidiary, Viracta Subsidiary, Inc. and Silicon Valley Ba..
CI
2021VIRACTA THERAPEUTICS : to Present at the Jefferies Virtual Healthcare Conference
AQ
2021VIRACTA THERAPEUTICS : Kol
PU
2021VIRACTA THERAPEUTICS : to Host Key Opinion Leader Webinar
AQ
2021VIRACTA THERAPEUTICS : Reports First Quarter 2021 Financial Results and Provides Clinical ..
PU
2021Viracta Therapeutics, Inc. Reports Consolidated Earnings Results for the First Quarter ..
CI
2021VIRACTA THERAPEUTICS : HC Wainwright Starts Viracta Therapeutics at Buy With $35 Price Tar..
MT
2021VIRACTA THERAPEUTICS : SVB Leerink Initiates Viracta Therapeutics at Outperform With $18 P..
MT
2021VIRACTA THERAPEUTICS : to Present at the 20th Annual Needham Virtual Healthcare Conference
AQ
2021VIRACTA THERAPEUTICS : Evercore ISI Starts Viracta Therapeutics at Outperform with $45 Pri..
MT
2021VIRACTA THERAPEUTICS : Agrees to Sell Potential Milestones, Royalties on Drug Candidates t..
MT
2021Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction
CI
2021Viracta Therapeutics, Inc. Announces Executive Changes
CI
2021VIRACTA : Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference
PR
2021VIRACTA THERAPEUTICS, INC.(NASDAQGS : VIRX) added to NASDAQ Composite Index
CI
2021Viracta Therapeutics, Inc. Announces Executive Changes
CI
2021Viracta Therapeutics, Inc. Announces Notice of Allowance for U.S. Patent Application Co..
CI
2020Viracta Therapeutics, Inc. announced that it has received $40 million in funding from a..
CI
2020Viracta Therapeutics, Inc. announced that it expects to receive $40 million in funding
CI
2020Viracta Therapeutics, Inc. Announces Board Changes
CI
2020Viracta Therapeutics, Inc. Announces Appointment of Roger J. Pomerantz, MD to its Board..
CI
2020Viracta Therapeutics, Inc. Appoints Lisa Rojkjaer as Chief Medical Officer
CI
2020Viracta Announces that it's Precision Oncology Research in EBV+ Cancers Highlighted at ..
CI
2019Viracta Announces Positive Phase 1B/2 Data Presented At Oral Presentation on Lead Progr..
CI
2019Viracta Therapeutics, Inc Receives Fast Track Designation for Nanatinostat Combination ..
CI
2019Viracta Therapeutics, Inc. announced that it has received funding from Taiwania Capital..
CI
2019Viracta Therapeutics, Inc. announced that it expects to receive $25.09788 million in fu..
CI
2019Viracta Therapeutics, Inc. Announces Management Changes
CI
2019Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associa..
CI
1  2Next